- Home
- ORGO vs MCI Comparison
ORGO vs MCI Comparison
Compare ORGO & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- MCI
- Stock Information
- Founded
- ORGO 1985
- MCI 1971
- Country
- ORGO United States
- MCI United States
- Employees
- ORGO N/A
- MCI N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- MCI Trusts Except Educational Religious and Charitable
- Sector
- ORGO Health Care
- MCI Finance
- Exchange
- ORGO Nasdaq
- MCI Nasdaq
- Market Cap
- ORGO 465.6M
- MCI 436.4M
- IPO Year
- ORGO N/A
- MCI N/A
- Fundamental
- Price
- ORGO $4.32
- MCI $21.69
- Analyst Decision
- ORGO Hold
- MCI
- Analyst Count
- ORGO 1
- MCI 0
- Target Price
- ORGO $6.00
- MCI N/A
- AVG Volume (30 Days)
- ORGO 918.0K
- MCI 40.4K
- Earning Date
- ORGO 08-07-2025
- MCI 01-01-0001
- Dividend Yield
- ORGO N/A
- MCI 8.46%
- EPS Growth
- ORGO N/A
- MCI N/A
- EPS
- ORGO N/A
- MCI 1.82
- Revenue
- ORGO $458,760,000.00
- MCI N/A
- Revenue This Year
- ORGO $1.10
- MCI N/A
- Revenue Next Year
- ORGO $9.93
- MCI N/A
- P/E Ratio
- ORGO N/A
- MCI $9.88
- Revenue Growth
- ORGO 5.35
- MCI N/A
- 52 Week Low
- ORGO $2.28
- MCI $12.96
- 52 Week High
- ORGO $6.71
- MCI $19.24
- Technical
- Relative Strength Index (RSI)
- ORGO 68.34
- MCI 57.60
- Support Level
- ORGO $3.59
- MCI $21.18
- Resistance Level
- ORGO $4.70
- MCI $21.97
- Average True Range (ATR)
- ORGO 0.23
- MCI 0.62
- MACD
- ORGO 0.12
- MCI -0.00
- Stochastic Oscillator
- ORGO 81.15
- MCI 70.70
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.